15. Cutter NC, Scott DD, Johnson JC, Whiteneck
30. Jarrett L, Nandi P, Thompson AJ. Managing se-
G. Gabapentin effect on spasticity in multiple
vere lower limb spasticity in multiple sclerosis:
1. Abrams P. Evidence for the efficacy and safety
sclerosis: a placebo-controlled, randomized
does intrathecal phenol have a role? J Neurol
of tolterodine in the treatment of overactive
trial. Arch Phys Med Rehabil 2000; 81: 164-9.
Neurosurg Psychiatry 2002; 73: 705-9.
bladder. Expert Opin Pharmacother 2001; 2:
16. DasGupta R, Fowler CJ. Bladder, bowel and
31. Kesselring J, Thompson AJ. Spasticity, ataxia
sexual dysfunction in multiple sclerosis. Mana-
and fatigue in multiple sclerosis. Baillière’s Clin
2. Albrecht H, Schwecht M, Pöllmann W, Parag D,
gement strategies. Drugs 2003; 63: 153-66.
Erasmus L-P, König N. Klinischer Nachweis
17. Dietz V, Young RR. The syndrome of spastic
32. Killestein J, Hoogervorst ELJ, Reif M, Kalkers
positiver Behandlungseffekte bei Patienten
paresis. In: Brandt T, Dichgans J (eds). Neuro-
NF, van Loenen AC, Staats PGM, Gorter RW,
mit multipler Sklerose. Nervenarzt 1998; 69:
logical Disorders: Course and treatment. New
Uitdehaag BMJ, Polman CH. Safety, tolerabil-
ity and efficacy of orally administered cannabi-
3. Appel RA, Sand P, Dmochowski R, Anderson
18. Dula E, Bukofzer S, Perdok R, George M, and
noids in MS. Neurology 2002; 58: 1404-7.
R, Zinner N, Lama D, Roach M, Miklos J, Saltz-
33. Krogh K, Christensen P, Laurberg S. Colorectal
stein D, Boone T, Staskin DR, Albrecht D for
blind, crossover comparison of 3 mg apomor-
symptoms in patients with neurological disease.
the Object Study Group. Prospective randomi-
phine SL with placebo and with 4 mg apomor-
Acta Neurol Scand 2001; 103: 335-43.
zed controlled trial of extended-release oxybu-
phine SL in male erectile dysfunction. Eur Urol
34. Krupp LB, Coyle PK, Doscher C, Miller A,
tynin chloride and tolterodine tartrate in the
Cross AH, Jandorf L, Halper J, Johnson B, Mor-
treatment of overactive bladder: results of
19. Fernández O. Mechanisms and current treat-
gante L, Grimson R. Fatigue therapy in mul-
the OBJECT Study. Mayo Clin Proc 2001; 76:
ments of urogenital dysfunction in multiple
tiple sclerosis: results of a double-blind, random-
ized, parallel trial of amantadine, pemoline and
4. Baker D, Pryce G, Croxford JL, Brown P, Pert-
20. Flachenecker P, Kümpfel T, Kallmann B, Gott-
placebo. Neurology 1995; 45: 1956-61.
schalk M, Grauer O, Rieckmann P,Trenkwalder
35. Kurtzke JF. Rating neurological impairment in
noids control spasticity and tremor in a multi-
C, Toyka KV. Fatigue in multiple sclerosis: a
multiple sclerosis: an expanded disability status
ple sclerosis model. Nature 2000; 404: 84-7.
comparison of different rating scales and corre-
scale (EDSS). Neurology 1983; 33: 1444-52.
5. Bayas A, Rieckmann P. Managing the adverse
lation to clinical parameters. Mult Scler 2002;
36. Lublin FD, Whitaker JN, Eidelman BH, Miller
effects of interferon-β therapy in multiple
sclerosis. Drug Safety 2000; 22: 149-59.
21. Fowler CJ. Neurological disorders of mictu-
patients receiving interferon beta-1b for mul-
6. Betts CD, Jones SJ, Fowler CG, Fowler CJ.
rition and their treatment. Brain 1999; 122:
tiple sclerosis: report of a consensus conference.
Erectile dysfunction in multiple sclerosis: asso-
ciated neurological and neurophysiological
22. Fowler C, Miller J, Sharief M for the Sildena-
37. Mertin J. Symptomatische Behandlung. In: Kes-
deficits, and treatment of the condition. Brain
fil Study Group. Viagra (sildenafil citrate) for
selring J (Hrsg). Multiple Sklerose. 3. Auflage.
the treatment of erectile dysfunction in men
Stuttgart: Kohlhammer 1997; 199-214.
7. Bramanti P, Sessa E, Rifici C, D´Aleo G, Flori-
with multiple sclerosis. Ann Neurol 1999; 46:
38. Metz L. Multiple sclerosis: symptomatic thera-
dia D, Di Bella P, Lublin F. Enhanced spasticity
pies. Semin Neurol 1998; 18: 389-95.
in primary progressive MS patients treated
23. Gold R, Toyka KV. Immuntherapie neurologi-
39. Morris K. Melanocortins key to trigger sex on
with interferon beta-1b. Neurology 1998; 51:
the brain. The Lancet Neurology 2003; 2: 140.
40. MS-Therapie Konsensus Gruppe (MSTKG).
8. Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde
24. Gracies J-M, Elovic E, McGuire J, Simpson D.
C. Treatments for fatigue in multiple sclerosis: a
Traditional pharmacological treatments for
rapid and systematic review. Health Technol
spasticity. Part II: General and regional treat-
ments. Muscle Nerve 1997; Suppl 6: S92-S120.
41. Mueller ME, Gruenthal M, Olson WL, Olson
9. Brar SP, Smith MB, Nelson LM, Franklin GM,
25. Hartung H-P, Gonsette R, König N, Kwiecinski
WH. Gabapentin for relief of upper motor neu-
Cobble ND. Evaluation of treatment protocols
H, Guseo A, Morrissey SP, Krapf H, Zwingers
ron symptoms in multiple sclerosis. Arch Phys
on minimal to moderate spasticity in multiple
T, and the Mitoxantrone in Multiple Sclerosis
sclerosis. Arch Phys Med Rehabil 1991; 72:
42. Müller-Lissner SA. Effect of wheat bran on
gressive multiple sclerosis: a placebo-con-
weight of stool and gastrointestinal transit
10. Caruso S, Intelisano G, Lupo L Agnello C. Pre-
trolled, double-blind, randomised, multicentre
time: a meta analysis. Br Med J 1988; 296: 615-7.
menopausal women affected by sexual arousal
43. Multiple Sklerose-Therapie-Konsensus-Grup-
disorder treated with sildenafil: a double-blind,
26. Hilton P, Hertogs K, Stanton SL. The use of
cross-over, placebo-controlled study. Br J Obs-
desmopressin (DDAVP) for nocturia in women
fentherapie der multiplen Sklerose, 1. Er-
with multiple sclerosis. J Neurol Neurosurg
gänzung: Dezember 2000. Nervenarzt 2001; 72:
11. Clanet MG, Brassat D. The management of
multiple sclerosis patients. Curr Opin Neurol
27. Hulter BM, Lundberg PO. Sexual function
44. Multiple-Sklerose-Therapie-Konsensus-Grup-
in women with advanced multiple sclerosis.
pe. Immunmodulatorische Stufentherapie der
12. Colombo B, Martinelli Boneschi F, Rossi P, Ro-
J Neurol Neurosurg Psychiatry 1995; 59: 83-6.
Multiplen Sklerose, Neue Aspekte und prakti-
varis M, Maderna L, Filippi M, Comi C. MRI
28. Hyman N, Barnes M, Bhakta B, Cozens A, Bak-
sche Umsetzung, März 2002. Nervenarzt 2002;
and motor evoked potential findings in nondis-
heit M, Kreczy-Kleedorfer B, Poewe W, Wissel
abled multiple sclerosis patients with and with-
J, Bain P, Glickman S, Sayer A, Richardson A,
45. Nance PW, Sheremata WA, Lynch SG, Vollmer
out symptoms of fatigue. J Neurol 2000; 247:
Dott C. Botulinum toxin (Dysport®) treatment
T, Hudson S, Francis GS, O´Connor P, Cohen
of hip adductor spasticity in multiple sclerosis:
JA, Schapiro RT, Whitham R, Mass MK, Lind-
13. Comi G, Leocani L, Rossi P, Colombo B. Phy-
a prospective, randomised, double blind, place-
sey JW, Shellenberger K. Relationship of the
siopathology and treatment of fatigue in multi-
bo controlled, dose ranging study. J Neurol
antispasticity effect of tizanidine to plasma con-
ple sclerosis. J Neurol 2001; 248: 174-9.
Neurosurg Psychiatry 2000; 68: 707-12.
centration in patients with multiple sclerosis.
14. Corbin JD, Francis SH, Webb DJ. Phospho-
29. Janardhan V, Bakshi R. Quality of life in pa-
diesterase type 5 as a pharmacologic target in
tients with multiple sclerosis: the impact of
46. Ochs G, Struppler A, Meyerson BA, Linderoth
erectile dysfunction. Urology 2002; 60 (Suppl
fatigue and depression. J Neurol Sci 2002; 205:
B, Gybels J, Gardner BP, Teddy P, Jamous A,
Weinmann P. Intrathecal baclofen for long-
term treatment of spasticity: a multi-centre
A, Dellas S, Maguire RP, Missimer J, Radü EW,
pyridine in the treatment of fatigue in multiple
study. J Neurol Neurosurg Psychiatry 1989; 52:
Steck A, Leenders KL. Reduced glucose meta-
bolism in the frontal cortex and the basal
61. The United Kingdom Tizanidine Trial Group.A
47. Padma-Nathan H, Eardley I, Kloner RA, La-
ganglia of multiple sclerosis patients with fati-
double-blind, placebo-controlled trial of tiza-
ties AM, Montorsi F. A 4-year update on the
gue: a 18F-fluorodeoxyglucose positron emis-
nidine in the treatment of spasticity caused by
safety of sildenafil citrate (Viagra®). Urology
sion tomography study. Neurology 1997; 48:
multiple sclerosis. Neurology 1994; 44 (Suppl
48. Padma-Nathan H, Hellstrom WJG, Kaiser FE,
54. Rossini PM, Pasqualetti P, Pozzilli C, Grasso
62. Valiquette G, Herbert J, Meade-D´Alisera P.
Labasky RF, Lue TF, Nolten WE, Norwood PC,
MG, Millefiorini E, Graceffa A, Carlesimo GA,
Desmopressin in the management of nocturia
Peterson CA, Shabsigh R, Tam PY, Place VA,
Zibellini G, Caltagirone C. Fatigue in progressi-
in patients with multiple sclerosis. A double-
Gesundheit N for the Medical Urethral Sys-
ve multiple sclerosis: results of a randomized,
blind, crossover trial. Arch Neurol 1996; 53:
tem For Erection (MUSE) Study Group. Treat-
double-blind, placebo-controlled, crossover
ment of men with erectile dysfunction with
trial of oral 4-aminopyridine. Mult Scler 2001;
63. Weinshenker BG, Penman M, Bass B, Ebers
transurethral alprostadil. N Engl J Med 1997;
GC, Rice GPA. A double-blind, randomized,
55. Sampson FC, Hayward A, Evans G, Morton R,
crossover trial of pemoline in fatigue associated
49. Paisley S, Beard S, Hunn A, Wight J. Clinical
Collett B. Functional benefits and cost/benefit
with multiple sclerosis. Neurology 1992; 42:
effectiveness of oral treatments for spasticity in
analysis of continous intrathecal baclofen infu-
multiple sclerosis: a systematic review. Mult
sion for the management of severe spasticity.
64. Wiesel PH, Norton C, Roy AJ, Storrie JB, Bo-
50. Penn RD, Savoy SM, Corcos D, Latash M,
56. Schapiro RT. Management of spasticity, pain,
treatment (biofeedback) for constipation and
Gottlieb G, Parke B, Kroin JS. Intrathecal bac-
and paroxysmal phenomena in multiple sclero-
faecal incontinence in multiple sclerosis. J Neu-
lofen for severe spinal spasticity. N Engl J Med
sis. Curr Neurol Neurosci Rep 2001; 1: 299-302.
rol Neurosurg Psychiatry 2000; 69: 240-3.
57. Schapiro RT. Pharmacological options for
65. Zifko UA, Rupp M, Schwarz S, Zipko HT,
51. Polman CH, Bertelsmann FW, de Waal R, van
the management of multiple sclerosis symp-
Maida EM. Modafinil in treatment of fatigue
toms. Neurorehabil Neural Repair 2002; 16:
in multiple sclerosis. Results of an open-label
AC, Koetsier JC. 4-Aminopyridine is superior
to 3,4-diaminopyridine in the treatment of pa-
58. Schwid SR, Covington M, Segal BM, Goodman
66. Zimmermann C, Hohlfeld R. “Fatigue” bei
tients with multiple sclerosis. Arch Neurol
AD. Fatigue in multiple sclerosis: current un-
multipler Sklerose. Nervenarzt 1999; 70: 566-74.
derstanding and future directions. J Rehabil
67. Zorzon M, Zivadinov R, Bosco A, Monti Bra-
52. Rammohan KW, Rosenberg JH, Lynn DJ, Blu-
gadin L, Moretti R, Bonfigli L, Morassi P, Iona
menfeld AM, Pollak CP, Nagaraja HN. Efficacy
59. Shakespeare DT, Boggild M, Young C. Anti-
LG, Cazzato G. Sexual dysfunction in multiple
and safety of modafinil (Provigil®) for the
spasticity agents for multiple sclerosis (Coch-
sclerosis: a case-control study. I. Frequency and
treatment of fatigue in multiple sclerosis: a two
rane Review). The Cochraine Library, Issue 1.
comparison of groups. Mult Scler 1999; 5:
centre phase 2 study. J Neurol Neurosurg Psy-
60. Sheean GL, Murray NMF, Rothwell JC, Miller
53. Roelcke U, Kappos L, Lechner-Scott J, Brunn-
DH, Thompson AJ. An open-labelled clinical
and electrophysiological study of 3,4 diamino-
GMB Medication List The following numbers are estimates of the amount of medications dispensed during a brigade. It is always a good idea to plan for a larger brigade because if the medications are not all distributed on a brigade, WE WILL FIND A USE FOR THEM. We are active all year long, and can always use them later. Vitamins: Children's infant vitamins A
POWER OF ATTORNEY (REAL ESTATE) IMPORTANT INFORMATION This power of attorney authorizes another person (your agent) to make decisions for you(the principal) and to act on your behalf concerning your real property. You should selectsomeone you trust to serve as your agent. Unless you specify otherwise, generally the agent’s authority will continue until you die orrevoke the power of